<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00517556</url>
  </required_header>
  <id_info>
    <org_study_id>25239</org_study_id>
    <nct_id>NCT00517556</nct_id>
  </id_info>
  <brief_title>Continuous Administration of Oral Contraceptive, Primary Dysmenorrhea</brief_title>
  <acronym>Dysmenorrhea</acronym>
  <official_title>Continuous Administration of a Monophasic Oral Contraceptive in the Treatment of Primary Dysmenorrhea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary hypothesis is that continuous administration of an OCP (CCOCP regimen) will
      result in more pain relief than a traditional 21/7 administration in primary dysmenorrhea
      (PD) patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is well established that excess prostaglandin production in primary dysmenorrhea (PD)
      leads to ischemia of the uterine muscle, which consequently causes pelvic pain. A large
      number of drugs have been studied for pain relief in dysmenorrhea patients with non-steroid
      anti-inflammatory drugs (NSAIDs) being the most effective with the overall success rate of
      more than 75%. Oral contraceptive pills (OCP) are also an established treatment for PD with
      the success rate of 70%. Lately, OCP's have been used continuously in patients with
      endometriosis and had better pain control than traditional administration of OCP.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Visual Analog Scale (VAS) Score</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Change in subjective perception of pain, as measured by the VAS. Subjects completed the VAS at baseline and 6 months. The VAS ranges from 0 (no pain) to 100 (worst pain). Therefore, a negative change in VAS indicates improvement in pain and a positive change in VAS indicates worsening of pain.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Dysmenorrhea</condition>
  <arm_group>
    <arm_group_label>study group (CCOCP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treatment with monophasic oral contraceptive (gestodene 0,075 mg /ethinyl estradiol 20 mcg) for 168 continuous days through six cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group (traditional OCP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment with monophasic oral contraceptive (gestodene 0,075 mg /ethinyl estradiol 20 mcg) for traditional (21 active days/7 inactive days) regimen through six cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CCOCP</intervention_name>
    <description>(CCOCP) continuous treatment with Monophasic oral gestodene/ethinyl estradiol</description>
    <arm_group_label>study group (CCOCP)</arm_group_label>
    <other_name>Oral contraceptives</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Traditional OCP</intervention_name>
    <description>(traditional OCP) (21 active days/7 inactive days) treatment regimen</description>
    <arm_group_label>control group (traditional OCP)</arm_group_label>
    <other_name>Oral contraceptives</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy women ages 18-35 with a history of PD (onset &lt; 3 years after menarche).

          -  Subjects must have had regular (25-31 day) menstrual cycles for the three month period
             preceding enrollment, with symptoms of moderate to severe PD during those cycles.

        Exclusion Criteria:

          -  Patients who have contraindications to OCP therapy.

          -  Known or suspected secondary dysmenorrhea (major abdominal or pelvic surgery,
             endometriosis, pelvic inflammatory disease (PID), ovarian cysts, pathological vaginal
             secretion, chronic abdominal pain, inflammatory bowel disease, irritable bowel
             syndrome).

          -  Concomitant treatment with oral contraceptives, GnRH agonists and antagonists,
             antiandrogens, gonadotropins, anti-obesity drugs.

          -  The use of contraceptive implants, injectable contraceptives or intrauterine devices.
             The washout period on all these medications will be 3 months.

          -  Migraines, depression requiring hospitalization or associated with suicidal ideation
             during previous estrogen or ocp use.

          -  Known or suspected hypersensitivity to trial drug.

          -  Patients enrolled simultaneously into other investigative studies that require meds.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard S Legro, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nova Gradiska General Hospital</name>
      <address>
        <city>Strossmayerova 17</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Croatia</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2007</study_first_submitted>
  <study_first_submitted_qc>August 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2007</study_first_posted>
  <results_first_submitted>January 26, 2017</results_first_submitted>
  <results_first_submitted_qc>March 20, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 28, 2017</results_first_posted>
  <last_update_submitted>March 20, 2017</last_update_submitted>
  <last_update_submitted_qc>March 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Richard S. Legro, M.D.</investigator_full_name>
    <investigator_title>Professor, Obstetrics and Gynecology and Public Health Sciences</investigator_title>
  </responsible_party>
  <keyword>Dysmenorrhea</keyword>
  <keyword>continuous OCP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysmenorrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Gestodene</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Study Group (CCOCP)</title>
          <description>treatment with monophasic oral contraceptive (gestodene 0,075 mg /ethinyl estradiol 20 mcg) for 168 continuous days through six cycles</description>
        </group>
        <group group_id="P2">
          <title>Control Group (Traditional OCP)</title>
          <description>treatment with monophasic oral contraceptive (gestodene 0,075 mg /ethinyl estradiol 20 mcg) for traditional (21 active days/7 inactive days) regimen through six cycles.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Group (CCOCP)</title>
          <description>treatment with monophasic oral contraceptive (gestodene 0,075 mg /ethinyl estradiol 20 mcg) for 168 continuous days through six cycles</description>
        </group>
        <group group_id="B2">
          <title>Control Group (Traditional OCP)</title>
          <description>treatment with monophasic oral contraceptive (gestodene 0,075 mg /ethinyl estradiol 20 mcg) for traditional (21 active days/7 inactive days) regimen through six cycles.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.47" spread="3.91"/>
                    <measurement group_id="B2" value="21.00" spread="4.03"/>
                    <measurement group_id="B3" value="20.74" spread="3.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Croatia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.20" spread="3.23"/>
                    <measurement group_id="B2" value="20.36" spread="1.77"/>
                    <measurement group_id="B3" value="20.78" spread="2.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Visual Analog Scale (VAS) Score</title>
        <description>Change in subjective perception of pain, as measured by the VAS. Subjects completed the VAS at baseline and 6 months. The VAS ranges from 0 (no pain) to 100 (worst pain). Therefore, a negative change in VAS indicates improvement in pain and a positive change in VAS indicates worsening of pain.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Group (CCOCP)</title>
            <description>treatment with monophasic oral contraceptive (gestodene 0,075 mg /ethinyl estradiol 20 mcg) for 168 continuous days through six cycles</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Traditional OCP)</title>
            <description>treatment with monophasic oral contraceptive (gestodene 0,075 mg /ethinyl estradiol 20 mcg) for traditional (21 active days/7 inactive days) regimen through six cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visual Analog Scale (VAS) Score</title>
          <description>Change in subjective perception of pain, as measured by the VAS. Subjects completed the VAS at baseline and 6 months. The VAS ranges from 0 (no pain) to 100 (worst pain). Therefore, a negative change in VAS indicates improvement in pain and a positive change in VAS indicates worsening of pain.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-74.8" lower_limit="-86.1" upper_limit="-63.5"/>
                    <measurement group_id="O2" value="-58.7" lower_limit="-70.3" upper_limit="-47.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Study Group (CCOCP)</title>
          <description>treatment with monophasic oral contraceptive (gestodene 0,075 mg /ethinyl estradiol 20 mcg) for 168 continuous days through six cycles</description>
        </group>
        <group group_id="E2">
          <title>Control Group (Traditional OCP)</title>
          <description>treatment with monophasic oral contraceptive (gestodene 0,075 mg /ethinyl estradiol 20 mcg) for traditional (21 active days/7 inactive days) regimen through six cycles.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Richard S. Legro, M.D.</name_or_title>
      <organization>The Milton S. Hershey Medical Center</organization>
      <phone>717-531-6210</phone>
      <email>rsl1@psu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

